AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06535087
Drug: Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Subcutaneous Allergen-Specific Immunotherapy:~   * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~  * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~   * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~  * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation.
Trial: NCT05729074
Drug: IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Trial: NCT05729074
Drug: IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
Trial: NCT05729074
Drug: IN-A002 Ointment 1% or IN-A002 Placebo Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Trial: NCT05729074
Drug: IN-A002 Ointment 3% or IN-A002 Placebo Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Trial: NCT05729074
Drug: IN-A002 Ointment 5% or IN-A002 Placebo Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Trial: NCT05729074
Drug: IN-A002 Ointment 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
Trial: NCT05729074
Drug: IN-A002 Ointment 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
Trial: NCT05729074
Drug: Elidel Cream 1% (pimecrolimus)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
Trial: NCT05923060
Drug: Topical Aminolevulinate
RxNorm normalized name: aminolevulinate Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Levulan Kerastick is applied to actinic keratoses.
Trial: NCT04857359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral matching placebo tablet
Trial: NCT06074094
Drug: Control Test
RxNorm normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients
Trial: NCT06532682
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor
Trial: NCT05401292
Drug: Isopropyl Alcohol 70% Topical Application Solution
RxNorm normalized name: Isopropyl Alcohol 70% Topical application Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First aid antiseptic
Trial: NCT04993690
Drug: LP-168 tablet
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects to take LP-168 orally with 240mL water, without food, Once daily or twice daily
Trial: NCT06687772
Drug: Anthracycline-based induction chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care, not dictated by protocol.
Trial: NCT05933291
Drug: steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate- or high-dose steroids
Trial: NCT02233829
Drug: Brain Dopamine Reactivity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of \[11C\]raclopride.
Trial: NCT06391372
Drug: estriol cream
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravaginal estriol via applicator twice a week before going to bed for 4 weeks
Trial: NCT04735185
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this intervention participants will receive a 1 mL intradiscal injection of the steroid methylprednisolone (40 mg/mL) into each affected disc.
Trial: NCT04735185
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this intervention participants will receive a 1 mL intradiscal injection of the local anesthetic bupivacaine 0.5% into each affected disc.
Trial: NCT05182203
Drug: biologic/targeted therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitors or the JAK inhibitors
Trial: NCT05279937
Drug: Dextrose 50% Intravenous Solution
RxNorm normalized name: Dextrose 50% Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
Trial: NCT05519839
Drug: Influenza Vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (deltoid) injections of Comparator influenza vaccine given on Day 0 and Day 70 (if applicable).
Trial: NCT00000681
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06266923
Drug: SPH6516 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH6516 tablets ： Orally, once daily, 25-200mg, 28 days a cycle
Trial: NCT06681389
Drug: NP-201 acetate injection (Part A)
RxNorm normalized name: NP Thyroid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration- Sub cutaneous. Dosage interval and frequency: MAD1-200mg daily for 5 days; MAD2- 300mg daily for 5 days, MAD3- 400mg daily for 5 days
Trial: NCT06681389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered across Part A and Part B
Trial: NCT06681181
Drug: GSK4528287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK4528287 will be administered.
Trial: NCT06681181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT05064345
Drug: HB0034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody
Trial: NCT05064345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palcebo
Trial: NCT04752696
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT04752696
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT05298085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment will be administered intranasally daily for 12 weeks.
Trial: NCT05982522
Drug: IN10018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally taken once daily
Trial: NCT05995912
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration (with or without food)
Trial: NCT05294640
Drug: 0.9% Bacteriostatic Local Anesthetic Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic corresponding to the study arm (0.9% bacteriostatic saline or 1% lidocaine with 1:100,000 epinephrine). Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
Trial: NCT05294640
Drug: 1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic consisting of a commercially available mixture of 1% lidocaine with 1:100,000 epinephrine. Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
Trial: NCT06202885
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy
Trial: NCT06615479
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06197139
Drug: [177Lu]Lu-XT117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at an interval of 6 weeks between each dose.
Trial: NCT06681766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.
Trial: NCT06679816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative placebo Reduction Therapy
Trial: NCT06681441
Drug: QRL-101 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
Trial: NCT06681441
Drug: QRL-101 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
Trial: NCT06681441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
Trial: NCT05583071
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT05248893
Drug: AGN-151586
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Injection
Trial: NCT04721977
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m\^2 administered BID via oral tablet
Trial: NCT05652751
Drug: physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
Trial: NCT05643066
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline was intravenously injected first.
Trial: NCT06182865
Drug: Ga-68 Dolacga Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga-68 Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
Trial: NCT04564833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration
Trial: NCT05093517
Drug: Placebo Subcutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for REMD-477 to which subjects will be randomized 1:2.
Trial: NCT06465069
Drug: LY4052031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT05104983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT06619483
Drug: BAY3018250 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT06619483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to BAY3018250
Trial: NCT06619483
Drug: BAY3018250 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT06107062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm
Trial: NCT04713358
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately Intravenous injection of normal saline 1ml after surgery
Trial: NCT06251050
Drug: Plcacebo mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Mouthwash is mainly composed of citric acid and sodium hydroxide, transparent colorless liquid. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
Trial: NCT06672016
Drug: Transdermal system containing progestin
RxNorm normalized name: CONTAINER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-130A-01 transdermal system, patch to be used for female contraception
Trial: NCT06598007
Drug: CT3001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.
Trial: NCT06592482
Drug: AZD0780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single A dose of AZD0780 will be administered in the morning on Day 1 under fasted condition. Study intervention will be administered orally with approximately 240 mL of water.
Trial: NCT06661746
Drug: Multimodal IV analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal IV analgesia of lidocaine, ketamine and MS
Trial: NCT05662358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo weekly
Trial: NCT04967755
Drug: Jing-Si-Herbal-Tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
Trial: NCT00001101
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06531720
Drug: Choline Salicylate 8.7 % Oral Gel
RxNorm normalized name: choline salicylate 8.7 % Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical preparation applied on oral mucosa lesion containing, ethanol-based
Trial: NCT06535412
Drug: Placebo + SOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection of Placebo
Trial: NCT05879744
Drug: CLN-978
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19xCD3 T cell engager
Trial: NCT04826692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
Trial: NCT06625775
Drug: BBO-10203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive assigned dose of BBO-10203 orally (PO) QD
Trial: NCT06209320
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administer to eyes
Trial: NCT06683846
Drug: Ivocizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via intravenous (IV) infusion
Trial: NCT06685289
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250mg/m2, oral, twice daily, treatment for 2 weeks with 1 week off, with 3 weeks as a treatment cycle (a total of 8 treatment cycles)
Trial: NCT05190341
Drug: Ibuprofen 800 mg oral
RxNorm normalized name: IBUPROFEN 800 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 hour before HSG
Trial: NCT05190341
Drug: Ketorolac 30mg oral
RxNorm normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 hour before HSG
Trial: NCT06686797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution/suspension
Trial: NCT06628310
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Infusion; IV Injection
Trial: NCT06628310
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Infusion; IV Injection
Trial: NCT04364672
Drug: 18F-labeled DPA-714 PET scan
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 within 4 weeks after completing NACT including at least 2 cycles administered; before surgery
Trial: NCT05026229
Drug: dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
Trial: NCT04827056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally, as individual films in the SL space.
Trial: NCT05319951
Drug: Oral Rehydration Salts power (iii)
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
Trial: NCT04341688
Drug: Gargle/Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period.
Trial: NCT06145490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, oral intake
Trial: NCT04586010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
Trial: NCT04297033
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lovastatin 40mg/d 12m
Trial: NCT06681870
Drug: ASP1893
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT04297033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05760937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06623630
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care
Trial: NCT06369298
Drug: JK07
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.
Trial: NCT06369298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride
Trial: NCT06521008
Drug: anti muscarinic drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a selective anti muscarinic drugs (5-10mg) once per day for 12 weeks.
Trial: NCT06624956
Drug: glucose, insulin, and potassium (GIK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK formulation: 100 g/L glucose, 33 U/L insulin, and 40 mmol/L KCl~Reference PMID: 32151220. Formulation represents a 50% reduction in compounded solute combination from the reference study, which allows for administration via peripheral IV.
Trial: NCT06672939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06681922
Drug: Cyclophosphamide, Bortezomib, Abatacept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug given for prevention of Graft-versus-Host Disease (GvHD) following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)